Newsroom
We publish timely news about our science, collaborations, and progress toward new therapies. FireGate maintains active, constructive engagement with research and regulatory bodies, including NIH and FDA partners, to promote transparency, rigor, and ethical advancement.
Coming FY26
FireGate Biotech is preparing for an exciting next phase.
- Grant updates: Details on federal and scientific grant activity will be shared soon.
- Integrity in focus: As we grow, our commitment to oversight, transparency, and accountability remains at the center of everything we do.
Pipeline Announcement
September 2025 — We published our initial pipeline: FG-001 (HIV), FG-002 (mTNBC), and FG-003 (MS). Each program leverages AI-driven insights to accelerate repurposing and novel therapeutic design. We welcome collaborative inquiries from research and clinical partners.